ClinicalTrials.gg
RecruitingNCT07577817Updated Jun 12, 2026

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.

An Early Phase 1 interventional study of CTX001 With and Without Iron and CTX001 With Iron in Anemia, Iron Deficiencies and Chronic Kidney Disease, sponsored by Cajal Therapeutics Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Cajal Therapeutics Inc. · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing iron in Anemia — 3 open to participants now, 3 under way, none of them phase 3. Iron · Anemia.

Planned enrollment
28th of 34
72 · median 275
Started
2026
with 1 other
Phase 1
Only one
of the 34
Registered
33rd of 34
by date
Lead sponsor
1 of 34
Cajal Therapeutics Inc.

Among the 34 studies testing iron in Anemia, this one is the 28th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 1, and was the 33rd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 34 studies testing iron in Anemia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About iron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing iron in Anemia, or all of them as a file.
02

Study summary

This study is testing CTX001 for certain conditions where the body does not have enough available iron or has difficulty storing or moving iron properly. The purpose of this study is to investigate any side effects that may happen with CTX001, how CTX001 is absorbed by and processed in the body, and how CTX001 affects iron levels in the blood when administered with or without iron and/or food.

Read the detailed description

The study drug CTX001 is an investigational treatment for certain diseases where the body does not have enough iron in the bone marrow (the hollow inner parts of bones). Iron is an important part of red blood cells, which are made in the bone marrow. When there is not enough iron in the bone marrow, it can lead to anaemia. Conditions like chronic kidney disease, bone marrow diseases, intestinal diseases, and bleeding disorders all can cause anaemia due to low iron levels, or iron that gets trapped in other body parts like the spleen and cannot get to the bone marrow. Although anemia can sometimes be treated with iron pills or iron infusions, some patients cannot tolerate these treatments and others do not respond to them because either their intestines don't absorb the iron or because the body has improperly stored the iron where it can't be used to make red blood cells. CTX001 is a pill that is swallowed by mouth. Inside the body, CTX001 is expected to bind to iron, help the iron be absorbed by the intestine and help the iron move out of body parts where it might be stuck. If effective, CTX001 could be used to treat anemia in patients with chronic health conditions.

03

Conditions studied

  • Anemia
  • Iron Deficiencies
  • Chronic Kidney Disease

Keywords

  • Red blood cells
  • Iron
  • Anemia
  • Chronic kidney disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving
  • Agrees to use effective
  • (BMI) between 18.0 and 32.0 kg/m2
  • Healthy by medical evaluation and medical history
  • Hematological parameters, serum iron, transferrin and ferritin are within normal range and transferrin saturation is within normal range and greater than or equal to 20%
  • Can swallow tablets and has suitable venous access for blood sampling

Exclusion criteria

Exclusion Criteria:

  • Has dietary requirements that may be difficult to accommodate
  • Is a regular user of cannabis or has a history of illicit drug abuse within 1 year
  • Has a history of alcohol abuse or binge drinking within 6 months
  • Is a regular user of tobacco or nicotine-containing products
  • Unwilling or unable to comply with the lifestyle guidelines described in the protocol
  • Has history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s) as determined by the Investigator
  • Has any concurrent disease or condition or physical, psychological, mental, and/or social reason that, in the opinion of the Investigator, would make the participant unsuitable for participation in the clinical study
  • Has received a blood transfusion within 1 year
  • Has donated whole blood within 6 months or plasma within 30 days
  • Requires prescription medication or regular use of non-prescription medication
  • Is an employee of the Sponsor, the CRO, or of any organization or site(s) associated with this study, or any immediate family member who is in a dependent relationship with a study site employee who is involved in the conduct of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Single Ascending Dose (CTX001)

    Up to 5 sequential, single ascending dose cohorts.

    Drug: CTX001 With and Without Iron

  • Placebo comparator
    Single Ascending Dose (Placebo)

    Up to 5 sequential, single ascending dose cohorts

    Drug: Placebo With and Without Iron

  • Experimental
    Food Effect (CTX001)

    Up to 3 sequential, single ascending dose food effect cohorts

    Drug: CTX001 With Iron

  • Placebo comparator
    Food Effect (Placebo)

    Up to 3 sequential, single ascending dose food effect cohorts

    Drug: Placebo With Iron

  • Experimental
    Multiple Ascending Dose (CTX001)

    Up to 3 multiple ascending dose cohorts.

    Drug: CTX001 Multiple Dose

  • Placebo comparator
    Multiple Ascending Dose (Placebo)

    Up to 3 multiple ascending dose cohorts

    Drug: Placebo Multiple Dose

Interventions

  • DrugCTX001 With and Without Iron

    There are two treatment periods. In the first, CTX001 is administered as a single dose (tablet) by itself. In the second, CTX001 is administered as a single dose (tablet) with iron.

  • DrugCTX001 With Iron

    Drug pages: Exagamglogene autotemcel · Iron

    There are two treatment periods. In one, CTX001 is administered as a single dose (tablet) with iron (tablet) following a high fat, high calorie meal. In the other, CTX001 is administered as a single dose (tablet) with iron (tablet) under fasting conditions.

  • CTX001 (tablet) is administered daily for 7 consecutive days.

  • DrugPlacebo With and Without Iron

    There are two treatment periods. In the first, placebo is administered as a single dose (tablet) by itself. In the second, placebo is administered as a single dose (tablet) with iron.

  • DrugPlacebo With Iron

    There are two treatment periods. In one, placebo is administered as a single dose (tablet) with iron (tablet) following a high fat, high calorie meal. In the other, placebo is administered as a single dose (tablet) with iron (tablet) under fasting conditions.

  • DrugPlacebo Multiple Dose

    Placebo (tablet) is administered daily for 7 consecutive days.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant, whether or not considered related to the study intervention. An AE was considered a treatment-emergent AE (TEAE) if the AE started after initial study drug administration and before the last study visit.

    Time frame: From first dose of study drug through the last study visit, approximately 15 days.

  2. Number of Participants with Serious TEAEs

    A serious AE (SAE) is defined as any AE that, at any dose, meets one or more of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital anomaly or birth defect; or any important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.

    Time frame: From first dose of study drug through the last study visit, approximately 15 days.

  3. Number of Participants with Clinically Significant Changes in Physical Examination

    Abnormalities in physical examinations were based on investigator's discretion.

    Time frame: From the first dose of study drug through the last study visit; approximately 15 days.

  4. Number of Participants with Clinically Significant Changes in Safety Laboratory Values

    Safety laboratory evaluations included blood counts, serum chemistries, coagulation studies, and urinalyses. Determination of clinical significance was based on investigator discretion.

    Time frame: From first dose of study drug through last study visit, approximately 15 days.

  5. Number of Participants with Clinically Significant Changes in Vital Signs

    Vital signs included heart rate, respiratory rate, blood pressure, and temperature. Determination of clinical significance was based on investigator discretion.

    Time frame: From the first dose of study drug through the last study visit, approximately 15 days.

  6. Number of Participants with Clinically Significant Changes in Electrocardiograms

    Electrocardiograms are tests that measure the electrical activity of the heart. Determination of clinical significance was based on investigator discretion.

    Time frame: From the first dose of study drug through the last study visit, approximately 15 days.

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of CTX001

    Time frame: Pre-dose, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  2. Time to Maximum Observed Plasma Concentration (Tmax) of CTX001

    Time frame: Pre-dose, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  3. Area Under the Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of CTX001

    Time frame: Pre-dose, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  4. Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of CTX001

    Time frame: Pre-dose, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  5. Apparent Clearance (CL/F) of CTX001

    Time frame: Pre-dose, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  6. Plasma Half-Life of CTX001

    Time frame: Pre-dose, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  7. Maximum Change in Serum Iron From Baseline

    Time frame: Pre-dose, 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  8. Maximum Change in Serum Transferrin From Baseline

    Time frame: Pre-dose, 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  9. Maximum Change in Serum Transferrin Saturation From Baseline

    Time frame: Pre-dose, 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

  10. Maximum Change in Serum Ferritin From Baseline

    Time frame: Pre-dose, 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours after the Day 1 and Day 8 doses (SAD and Food Effect Cohorts) or the Day 1 and Day 7 doses (MAD Cohorts).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2026, 4 months later.

Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's planned 4 months is below that.

Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartEst.
Jun 2026
Primary completionEst.
Oct 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07577817
Lead sponsor
Cajal Therapeutics Inc.
Responsible party
Sponsor
First posted
May 11, 2026
Start date
Jun 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jun 12, 2026

Study contacts

Anthony Johnson
Contact
a.johnson@nucleusnetwork.com.au
+61 07 3707 2787
Aarthy Joseph, Dr
principal investigator · Nucleus Network

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Exagamglogene autotemcel · Iron

Start the discussion